## ADUS: Addus HomeCare Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.0% below STRENGTH zone (3.0-6.0%); PEG 1.11 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($108.54)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.02M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Blackrock Inc.: 14.8% (-1.1%)
- Vanguard Group Inc: 7.0% (+2.9%)
- Capital Research Glo: 6.5% (+9.0%)
- Wasatch Advisors LP: 5.1% (+0.8%)
- Silvercrest Asset Ma: 4.6% (+14.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +7.0% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.11 suggests fair value with growth premium. Balance sheet: low leverage (D/E 0.36). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.1B |
| Beta | 0.94 |
| 52W Range | $88.96 - $136.72 |
| Short Interest | 4.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.11 |
| Forward P/E | 16.8 |
| Current P/E | 18.7 |
| YoY Growth | 11.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -5.0% to 2.0% (+7.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.0pp (needs >3.0% for momentum thesis). MRS_5 at 2.3% confirms short-term momentum alignment. RSI neutral at 50. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.04% (CS: 49) | Neutral |
| RSI_14 | 50.2 | Neutral |
| MACD Histogram | -0.12 | Bearish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 0.996x | Below |
| vs SMA200 | 1.048x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $115.14
- **Stop Loss:** $108.54 (5.7% risk)
- **Target:** $121.74 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 181
- **Position Value:** $20,840.34
- **Portfolio %:** 20.84%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-23 (Est: $1.72)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.53 | $1.56 | +1.7% |
| 2025Q2 | $1.46 | $1.49 | +1.8% |
| 2025Q1 | $1.33 | $1.42 | +6.5% |
| 2024Q4 | $1.36 | $1.38 | +1.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*